Want to see SCND full AI Analyst Report?
Scientific Industries (SCND) AI Stock Analysis
Scientific Industries
(Other OTC:SCND)
SCND scores in the low range, driven primarily by severely deteriorating fundamentals: a 43.6% revenue decline, persistent losses, sharp margin compression, and accelerating cash burn that is rapidly consuming a shrinking equity base. A debt-light balance sheet is the only meaningful financial cushion. Technicals provide partial offset, with the price holding above its 50-, 100-, and 200-day moving averages, though short-term indicators are soft. Valuation offers no support given negative earnings and no dividend, while recently secured executive employment agreements add a small positive for leadership stability. Overall, this is a high-risk micro-cap situation requiring an operational turnaround or external capital.
Scientific Industries (SCND) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $7.75M
- Dividend Yield
- ―
- Average Volume (3M)
- 6,264
- Price to Earnings (P/E)
- -13.0
- Beta (1Y)
- 0.31
- Revenue Growth
- -44.48%
- EPS Growth
- 90.56%
- Country
- US
- Employees
- 55
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Hardware, Equipment & Parts
Scientific Industries Business Overview & Revenue Model
Company Description
Scientific Industries, Inc. operates as a global enterprise specializing in the development, production, and distribution of a comprehensive range of benchtop laboratory instrumentation and advanced bioprocessing systems. Their product line features...
Scientific Industries Earnings Call Summary
The earnings call highlighted significant growth in the VIVID pill counter business and successful cost-cutting initiatives, alongside promising developments and strategic partnerships in the bioprocessing segment. However, challenges in the European market remain a concern.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the third quarter of 2024, Scientific Industries demonstrated significant progress in its strategic transformation into a life sciences tool business with notable growth in sales, margins, and recurring revenue. The legacy Genie business experienced a recovery, generating positive cash flow that supports investments in the VIVID pill counter business, which saw a 50% increase in sales compared to the previous quarter and 12% year-over-year growth. The company is excited about the upcoming launch of the VIVID workstation, a new all-in-one pill counter and pharmacy management system. In the bioprocessing segment, sales increased by 12% compared to the previous year, with a remarkable 61% year-over-year growth in the U.S. market. Efforts to improve cost efficiency resulted in a reduction of operating expenses by over $1 million, or 22%, compared to the previous year. The company also reported a positive EBITDA margin of 14% for its U.S. entity in September, marking a significant milestone. Scientific Industries continues to invest in R&D and commercial activities, with a growing commercial pipeline and the successful launch of the DOTS platform, reflecting its potential to deliver long-term shareholder value.
Scientific Industries Financial Statement Overview
Summary
Financials are very weak across the board. Revenue collapsed 43.6% in 2025 to $5.1 million, gross margin compressed from the mid-40% range to 25.8%, and the company has been unprofitable in every year reviewed. Cash burn is accelerating, with operating cash flow of -$8.1 million and free cash flow of -$8.2 million, far exceeding the reported net loss of -$1.2 million. The only relative support is a nearly debt-free balance sheet (debt-to-equity ~9.1%), but equity has eroded from $26.2 million to $10.7 million and total assets have more than halved since mid-2022, pointing to a real risk of dilutive financing or liquidity strain without a turnaround.
Income Statement
8Very NegativeBalance Sheet
35NegativeCash Flow
6Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Jun 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.73M | 5.05M | 10.71M | 11.11M | 10.48M | 9.78M |
| Gross Profit | 1.67M | 1.30M | 4.73M | 5.10M | 4.64M | 4.98M |
| EBITDA | -6.79M | -7.89M | -5.89M | -8.51M | -7.41M | -4.46M |
| Net Income | -742.30K | -1.22M | -6.45M | -9.09M | -8.15M | -3.11M |
Balance Sheet | ||||||
| Total Assets | 10.11M | 12.61M | 11.56M | 16.73M | 18.07M | 29.01M |
| Cash, Cash Equivalents and Short-Term Investments | 4.55M | 6.66M | 2.57M | 5.72M | 6.20M | 13.42M |
| Total Debt | 790.70K | 966.70K | 1.00M | 1.33M | 1.43M | 1.49M |
| Total Liabilities | 2.03M | 1.94M | 2.44M | 2.85M | 3.28M | 2.78M |
| Stockholders Equity | 8.07M | 10.66M | 9.12M | 13.89M | 14.79M | 26.22M |
Cash Flow | ||||||
| Free Cash Flow | -6.60M | -8.21M | -3.78M | -6.29M | -6.20M | -3.56M |
| Operating Cash Flow | -6.95M | -8.15M | -3.68M | -6.16M | -5.70M | -3.30M |
| Investing Cash Flow | 3.99M | 3.83M | 2.87M | -735.10K | 3.61M | -10.88M |
| Financing Cash Flow | 500.00K | 1.95M | 645.70K | 5.75M | 2.31M | 16.31M |
Scientific Industries Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCND, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.76, and below the 200-day MA of 0.69, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 25.38 is Positive, neither overbought nor oversold. The STOCH value of 4.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCND.
Scientific Industries Risk Analysis
Scientific Industries disclosed 12 risk factors in its most recent earnings report. Scientific Industries reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksScientific Industries Peers Comparison
Overall Rating
ELTK46Neutral- SCND45Neutral
SVRE39Underperform
SOBR38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| ELTK | 46Neutral | $42.41M | -6.93 | -13.57% | 3.01% | -2.20% | -297.64% |
| SCND | 45Neutral | $7.75M | -13.00 | -7.37% | ― | -44.48% | 90.56% |
| SVRE | 39Underperform | $343.43M | -0.03 | -329.57% | ― | -68.00% | 97.75% |
| SOBR | 38Underperform | $355.56K | -0.04 | -310.87% | ― | 17.67% | 92.17% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SCND | Scientific Industries | 0.65 | 0.01 | 1.56% | |
| ELTK | Eltek | 6.31 | -4.99 | -44.16% | |
| IMTE | Integrated Media Technology | 0.45 | -0.36 | -44.55% | |
| SOBR | Sobr Safe, Inc. | 0.07 | -3.02 | -97.86% | |
| OST | Ostin Technology Group Co., Ltd. | 1.70 | 0.00 | 0.00% | |
| SVRE | SaverOne 2014 Ltd. ADR | 0.65 | -14.14 | -95.60% |
Scientific Industries Corporate Events
Scientific Industries Strengthens Executive Leadership Through New Agreements
PositiveOn October 1, 2026, Scientific Industries entered into a new employment agreement with Chief Financial Officer Zachary Rovinsky, securing his role through September 30, 2028 with an annual salary of $210,000, a bonus opportunity up to 10%, and schedu...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 02, 2026